Chemoimmunotherapy triggers immune responses targeting microsatellite stable colorectal cancer

ABSTRACTCheckpoint blockade immunotherapy transforms many types of cancer; however, in the field of metastatic colorectal cancer, checkpoint blockers are only effective in microsatellite-unstable tumors, which represent only a minority of patients. Microsatellite-stable tumors are thought to be immu...

Full description

Bibliographic Details
Main Authors: Marion Thibaudin, Francois Ghiringhelli
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:OncoImmunology
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2023.2257098
_version_ 1797367163047116800
author Marion Thibaudin
Francois Ghiringhelli
author_facet Marion Thibaudin
Francois Ghiringhelli
author_sort Marion Thibaudin
collection DOAJ
description ABSTRACTCheckpoint blockade immunotherapy transforms many types of cancer; however, in the field of metastatic colorectal cancer, checkpoint blockers are only effective in microsatellite-unstable tumors, which represent only a minority of patients. Microsatellite-stable tumors are thought to be immunoresistant. A recent publication demonstrates that, contrary to the standard view point, the combination of chemo-immunotherapy could trigger a tumor-specific immune response, leading to clinical benefit.
first_indexed 2024-03-08T17:13:25Z
format Article
id doaj.art-f451b3f0b7a7407097944215a0f8019d
institution Directory Open Access Journal
issn 2162-402X
language English
last_indexed 2024-03-08T17:13:25Z
publishDate 2023-12-01
publisher Taylor & Francis Group
record_format Article
series OncoImmunology
spelling doaj.art-f451b3f0b7a7407097944215a0f8019d2024-01-03T19:25:37ZengTaylor & Francis GroupOncoImmunology2162-402X2023-12-0112110.1080/2162402X.2023.2257098Chemoimmunotherapy triggers immune responses targeting microsatellite stable colorectal cancerMarion Thibaudin0Francois Ghiringhelli1University of Bourgogne, Dijon, FranceUniversity of Bourgogne, Dijon, FranceABSTRACTCheckpoint blockade immunotherapy transforms many types of cancer; however, in the field of metastatic colorectal cancer, checkpoint blockers are only effective in microsatellite-unstable tumors, which represent only a minority of patients. Microsatellite-stable tumors are thought to be immunoresistant. A recent publication demonstrates that, contrary to the standard view point, the combination of chemo-immunotherapy could trigger a tumor-specific immune response, leading to clinical benefit.https://www.tandfonline.com/doi/10.1080/2162402X.2023.2257098Checkpoint blockadeclinical trialcolorectal cancerimmunogenic cell death
spellingShingle Marion Thibaudin
Francois Ghiringhelli
Chemoimmunotherapy triggers immune responses targeting microsatellite stable colorectal cancer
OncoImmunology
Checkpoint blockade
clinical trial
colorectal cancer
immunogenic cell death
title Chemoimmunotherapy triggers immune responses targeting microsatellite stable colorectal cancer
title_full Chemoimmunotherapy triggers immune responses targeting microsatellite stable colorectal cancer
title_fullStr Chemoimmunotherapy triggers immune responses targeting microsatellite stable colorectal cancer
title_full_unstemmed Chemoimmunotherapy triggers immune responses targeting microsatellite stable colorectal cancer
title_short Chemoimmunotherapy triggers immune responses targeting microsatellite stable colorectal cancer
title_sort chemoimmunotherapy triggers immune responses targeting microsatellite stable colorectal cancer
topic Checkpoint blockade
clinical trial
colorectal cancer
immunogenic cell death
url https://www.tandfonline.com/doi/10.1080/2162402X.2023.2257098
work_keys_str_mv AT marionthibaudin chemoimmunotherapytriggersimmuneresponsestargetingmicrosatellitestablecolorectalcancer
AT francoisghiringhelli chemoimmunotherapytriggersimmuneresponsestargetingmicrosatellitestablecolorectalcancer